Research graph
References from Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2023 · External reference
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
10.1200/jco.2017.75.3657 · 2018 · External reference
Unresolved reference
2025 · External reference
ESUR: opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer
10.1007/s00330-025-12089-9 · 2026 · External reference
METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer
10.1016/j.eururo.2016.05.033 · 2017 · External reference
Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer
10.1186/s40644-023-00644-w · 2023 · External reference
Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing
10.1007/s00330-022-08536-6 · 2022 · External reference
The STAMPEDE2 trial: a site survey of current patterns of care, access to imaging and treatment of metastatic prostate cancer
10.1016/j.clon.2023.07.009 · 2023 · External reference
Unmet needs in the prediction and detection of metastases in prostate cancer
10.1634/theoncologist.2013-0027 · 2013 · External reference
The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer
10.1038/s41585-022-00618-w · 2022 · External reference
Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis reporting and data system for prostate cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels
10.1186/s40644-020-00350-x · 2020 · External reference
Value of whole-body magnetic resonance imaging using the MET-RADS-P criteria for assessing the response to intensified androgen deprivation therapy in metastatic hormone-naïve and castration-resistant prostate cancer
10.1016/j.euo.2024.10.009 · 2025 · External reference
Prostate-specific antigen response as a prognostic factor for overall survival in patients with prostate cancer treated with androgen receptor pathway inhibitors: a systematic review and meta-analysis
10.1016/j.euf.2025.03.019 · 2025 · External reference
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
10.1016/s0140-6736(18)32486-3 · 2018 · External reference
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
10.1186/s13014-024-02559-7 · 2024 · External reference
